IN2012DN00624A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00624A
IN2012DN00624A IN624DEN2012A IN2012DN00624A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A IN 624DEN2012 A IN624DEN2012 A IN 624DEN2012A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A
Authority
IN
India
Prior art keywords
fatigue
treatments
diseases
prevention
compositions
Prior art date
Application number
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Susan Marie Melnick
Duncan Taylor
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of IN2012DN00624A publication Critical patent/IN2012DN00624A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the compounds and compositions of the invention and use thereof for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments. Figure 1A
IN624DEN2012 2009-06-22 2010-06-21 IN2012DN00624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (1)

Publication Number Publication Date
IN2012DN00624A true IN2012DN00624A (en) 2015-06-12

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
IN624DEN2012 IN2012DN00624A (en) 2009-06-22 2010-06-21

Country Status (12)

Country Link
US (5) US8741950B2 (en)
EP (1) EP2445490B1 (en)
JP (3) JP6095366B2 (en)
KR (3) KR102021075B1 (en)
CN (2) CN106727486A (en)
AU (1) AU2010270971B2 (en)
BR (1) BRPI1015233A2 (en)
IN (1) IN2012DN00624A (en)
MX (1) MX2012000034A (en)
RU (1) RU2567801C2 (en)
TW (1) TWI453014B (en)
WO (1) WO2011005473A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254899B2 (en) 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
RU2567801C2 (en) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Methods for treating and preventing fatigue
WO2011055944A2 (en) * 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (en) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 Methods for treating Attention-Deficit/Hyperactivity Disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
EP2670406B1 (en) * 2011-12-21 2015-09-02 InnoBioscience, LLC Combination therapy with interferon beta and andrographolides for multiple sclerosis
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
JP2016530240A (en) * 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ Promotion of smoking cessation
PL3021838T3 (en) * 2013-07-18 2021-03-08 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
PL3065751T3 (en) * 2013-11-08 2020-07-13 Legacy Healthcare Ltd Method for treatment of cancer and cancer comorbidities
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (en) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 Aminocarbonyl carbamate compound
CN120574152A (en) 2016-09-06 2025-09-02 爱尔兰贾兹制药有限公司 (R)-2-amino-3-phenylpropylcarbamate hydrochloride solvate crystals, preparation method, composition and use thereof
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
CN110139905B (en) * 2016-12-30 2021-09-28 株式会社东进世美肯 Coating composition and film prepared therefrom
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR THE TREATMENT OF EXCESSIVE DROWSINESS
MX2020001146A (en) 2017-07-31 2020-08-20 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof.
JP7428480B2 (en) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 Compositions for improving sleep and foods, medicines, and feed containing the compositions
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (en) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 A composition for treating Kca3.1 channel mediated diseases comprising phenylalkyl carbamate compounds
AU2022390879A1 (en) * 2021-11-16 2024-06-13 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (en) * 1994-09-09 1999-06-15 남창우 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
KR0173862B1 (en) 1995-02-11 1999-04-01 조규향 O-carbamoyl- (D) -phenylalaninol compounds and their pharmaceutically useful salts and methods for their preparation
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (en) * 1995-04-10 1999-04-01 조규향 O-carbamoyl-phenylalanineol compounds having substituents on phenyl, pharmaceutically useful salts thereof, and preparation methods thereof
AU4567597A (en) 1996-10-08 1998-05-05 Institute Of Child Health Mutant ciita molecule and uses thereof
DE69618663T2 (en) * 1996-10-10 2002-08-14 Sk Corp., Seoul/Soul O-CARBAMOYL-PHENYLALANINOL COMPOSITIONS AND THEIR PHARMACEUTICAL APPLICABLE SALTS
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (en) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
KR20070083826A (en) * 2004-10-28 2007-08-24 에스케이 주식회사 Supplementary Therapy for Depression
AU2006254899B2 (en) * 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
DE602006012670D1 (en) 2005-06-22 2010-04-15 Sk Holdings Co Ltd TREATMENT OF SEXUAL DYSFUNCTION
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
RU2567801C2 (en) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Methods for treating and preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783632B1 (en) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 Methods for treating Attention-Deficit/Hyperactivity Disorder
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
JP6215740B2 (en) * 2014-03-14 2017-10-18 本田技研工業株式会社 Part fastening structure

Also Published As

Publication number Publication date
TWI453014B (en) 2014-09-21
US20200061017A1 (en) 2020-02-27
CA2765463A1 (en) 2011-01-13
MX2012000034A (en) 2012-02-21
JP2018188450A (en) 2018-11-29
JP2015214564A (en) 2015-12-03
CN106727486A (en) 2017-05-31
KR102021075B1 (en) 2019-11-04
US20170000756A1 (en) 2017-01-05
US20180263950A1 (en) 2018-09-20
US20120142769A1 (en) 2012-06-07
CA2765463C (en) 2018-10-09
EP2445490A4 (en) 2019-10-23
WO2011005473A9 (en) 2011-05-12
KR20170086710A (en) 2017-07-26
RU2567801C2 (en) 2015-11-10
RU2012101947A (en) 2013-07-27
BRPI1015233A2 (en) 2018-02-20
AU2010270971B2 (en) 2015-08-20
JP2012530779A (en) 2012-12-06
KR20190105675A (en) 2019-09-17
CN102481274A (en) 2012-05-30
JP6368285B2 (en) 2018-08-01
KR20120098578A (en) 2012-09-05
JP6095366B2 (en) 2017-03-15
WO2011005473A2 (en) 2011-01-13
KR102173587B1 (en) 2020-11-04
US8741950B2 (en) 2014-06-03
EP2445490A2 (en) 2012-05-02
US9464041B2 (en) 2016-10-11
EP2445490B1 (en) 2023-02-08
TW201105320A (en) 2011-02-16
AU2010270971A1 (en) 2012-01-19
US20140243406A1 (en) 2014-08-28
US9999609B2 (en) 2018-06-19
US10507192B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
MX2012000034A (en) Methods for treating or preventing fatigue.
IN2012DN03883A (en)
MX351464B (en) Methods for the treatment of allergic diseases.
MX364200B (en) Novel compositions and methods for the treatment of immune related diseases.
MY172372A (en) Compositions and methods for lowering triglycerides
MX2011009539A (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2294184A4 (en) Treatment of eye diseases and excessive neovascularization using a combined therapy
MX2011007930A (en) Crystalline insulin-conjugates.
MY161495A (en) Virus like particle compositions and methods of use
IN2012DN02471A (en)
IN2012DN02081A (en)
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
MX2009013353A (en) Telomerase activating compounds and methods of use thereof.
MX343135B (en) Fumagillol type compounds and methods of making and using same.
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
EA201001639A1 (en) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
TN2011000482A1 (en) Organic compounds and their uses
MX2009009761A (en) Compositions and kits for treating influenza.
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism
TNSN08400A1 (en) Organic compounds and their uses
MX2011011950A (en) Sublingual dexmedetomidine compositions and methods of use thereof.
MX342947B (en) Treatment of type 2 diabetes.
WO2013098416A3 (en) Pain relief compounds